

Dideoxynucleosides

[View the current Dideoxynucleosides InDepth page on BioPortfolio.com \(PDF\)](#)
(<http://www.bioportfolio.com/indepth/Dideoxynucleosides.html>) - Regularly Updated.

Recent Publications on Dideoxynucleosides:



- [Efficient and rapid template-directed nucleic acid copying using 2'-amino-2',3'-dideoxyribonucleoside-5'-phosphorimidazolidine monomers.](#)
*The development of a sequence-general nucleic acid copying system is an...*17th November, 2009
Howard Hughes Medical Institute and Department of Molecular Biology and- J Am Chem Soc. 2009 Oct 14;131(40):14560-70. ([DOI Direct Link](#))
- [Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.](#)
*Although the approved nucleoside reverse transcriptase (RT) inhibitors...*6th November, 2009
Department of Medicine, Division of Infectious Diseases, University of- Antimicrob Agents Chemother. 2009 Sep;53(9):3715-9. Epub 2009 Jul 13. ([DOI Direct Link](#))
- [Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: A brief history of stavudine \(D4T\) and its comparison with other dideoxynucleosides.](#)
*The occasion of this 25th anniversary issue encouraged us to reminisce...*27th October, 2009
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, United- Antiviral Res. 2009 Oct 23. ([DOI Direct Link](#))
- [Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.](#)
*We determined the ability of PET with the thymidine analog...*23rd October, 2009
Department of Internal Medicine II, Technische Universitat Munchen,- J Nucl Med. 2009 Sep;50(9):1441-7. Epub 2009 Aug 18. ([DOI Direct Link](#))
- [18F-FLT and 18F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models.](#)
*PURPOSE: To determine the dependence of celecoxib on the tumour...*16th October, 2009
Lab of Experimental Radiotherapy, Department of Radiation Oncology and- Int J Radiat Biol. 2009 Sep;85(9):763-71. ([DOI Direct Link](#))
- [Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.](#)
*BACKGROUND: Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir...*16th October, 2009
Rush University Medical Center, Chicago, Illinois 60612, USA.- AIDS. 2009 Jul 31;23(12):1547-56. ([DOI Direct Link](#))
- [\[Current data on antiretroviral therapy. CROI 2009: tenofovir DR convinces by high effectiveness and tolerance\]](#)
*The occasion of this 25th anniversary issue encouraged us to reminisce...*14th October, 2009

- MMW Fortschr Med. 2009 Apr 30;151(18):76-9.
- [Imaging biomarkers predict response to anti-HER2 \(ErbB2\) therapy in preclinical models of breast cancer.](#)
*PURPOSE: To evaluate noninvasive imaging methods as predictive biomarkers...*29th September, 2009
 Vanderbilt University Institute of Imaging Science, Department of- Clin Cancer Res. 2009 Jul 15;15(14):4712-21. Epub 2009 Jul 7. ([DOI Direct Link](#))
- [PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.](#)
*PURPOSE: Checkpoint kinase 1 (Chk1) plays a critical role in the...*29th September, 2009
 Oncology Research Unit, Pfizer Global Research and Development, La Jolla- Clin Cancer Res. 2009 Jul 15;15(14):4630-40. Epub 2009 Jul 7. ([DOI Direct Link](#))
- [Virological response to initial antiretroviral regimens containing abacavir or tenofovir.](#)
*Patients with a baseline viral load >100,000 copies/mL receiving abacavir...*25th September, 2009
 Research Department of Infection and Population Health, University College- J Infect Dis. 2009 Sep 1;200(5):710-4. ([DOI Direct Link](#))
- [Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF \(study COL40263\).](#)
*COL40263 was a pilot 48-week, open-label, multicenter study evaluating the...*23rd September, 2009
 GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA.- AIDS Res Hum Retroviruses. 2009 Jul;25(7):665-72. ([DOI Direct Link](#))
- [Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production.](#)
*OBJECTIVE: The purpose of this study was to investigate the mechanism by...*9th September, 2009
 Department of Vascular Medicine, Academic Medical Center, Amsterdam, The- Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1336-41. Epub 2009 Aug 10. ([DOI Direct Link](#))
- [Use of 11F-fluorothymidine positron emission tomography in brain tumor\]](#)
*Positron emission tomography (PET) with...*4th September, 2009
 Department of Neurological Surgery, Kagawa University School of Medicine,- No Shinkei Geka. 2009 Jul;37(7):657-64.
- [The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.](#)
*COL40263 was a pilot 48-week, open-label, multicenter study evaluating the...*25th July, 2009
 - J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):361-2. ([DOI Direct Link](#))
- [Report from the 16th Conference on Retroviruses and Opportunistic Infections. Continued concern about abacavir and cardiovascular risk.](#)
*COL40263 was a pilot 48-week, open-label, multicenter study evaluating the...*27th June, 2009
 - AIDS Clin Care. 2009 Apr;21(4):32-3.

Dideoxynucleosides Patents:



- 7422872- [Thermus thermophilus nucleic acid polymerases](#)
- 7462721- [Aza-quinolinol phosphonate integrase inhibitor compounds](#)

- 7468243- [2-aminopyrimidin-4-one nucleic acid labeling compounds](#)
- 7468357- [Nucleosides with anti-hepatitis B virus activity](#)
- 7468436- [Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers](#)
- 7482334- [Therapeutic treatment methods](#)
- 7491798- [Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins](#)
- 7491818- [Nucleic acid labeling compounds](#)
- 7495006- [2' and 3'-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation](#)
- 7501251- [DNA diagnostics based on mass spectrometry](#)
- 7504420- [Compounds which inhibit beta-secretase activity and methods of use](#)
- 7462605- [Phosphoramidate compounds and methods of use](#)
- 7456155- [2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections](#)
- 7452672- [Methods of analyzing polynucleotides employing energy transfer dyes](#)
- 7423140- [Oligonucleotides and analogs labeled with energy transfer dyes](#)
- 7423143- [Nucleic acid labeling compounds](#)
- 7432058- [Methods of labeling nucleic acids with energy transfer dyes](#)
- 7432272- [Antiviral analogs](#)
- 7439350- [Nucleotide analogs](#)
- 7439351- [2' or 3' -deoxy and 2', 3'-dideoxy-.beta.-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents](#)
- 7442527- [Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents](#)
- 7442718- [Inhibitors of aspartyl protease](#)
- 7449149- [Kits useful for sequencing nucleic acids](#)
- 7449298- [Methods of analyzing polynucleotides employing energy transfer dyes](#)
- 7511027- [Method of treating hepatitis delta virus infection](#)
- 7531670- [Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives](#)
- 7589066- [Potent and specific immunoproteasome inhibitors](#)
- 7589078- [Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections](#)
- 7592368- [Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors](#)
- 7595162- [Methods of labeling polynucleotides with energy transfer dyes](#)
- 7595390- [Industrially scalable nucleoside synthesis](#)
- 7598373- [Process for the production of 2-C-methyl-D-ribonolactone](#)
- 7605144- [Enzyme catalyzed therapeutic compounds](#)
- 7608260- [Stabilized immunoglobulins](#)
- 7608597- [Methods and compositions for treating hepatitis C virus](#)
- 7608600- [Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections](#)
- 7588769- [Viruses encoding mutant membrane protein](#)
- 7585851- [3'-prodrugs of 2'-deoxy-.beta.-L-nucleosides](#)
- 7585657- [Signal for packaging of influenza virus vector](#)
- 7541342- [Use of PKC-activating compounds as cardioprotectants and as apoptosis-inducing anti-tumor agents](#)
- 7547687- [Therapeutic treatment methods](#)
- 7547704- [Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections](#)
- 7550256- [Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease](#)
- 7550570- [4,7-dichlororhodamine dyes labeled polynucleotides](#)
- 7572620- [H3 equine influenza A virus](#)
- 7579143- [Method of assessing the effectiveness of a non-nucleoside reverse transcriptase inhibitor \(NNRTI\) on a human immunodeficiency virus type 1 \(HIV-1\)-infected patient](#)
- 7582618- [2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections](#)

- 7582748- [Methods of manufacture of 2'-deoxy-.beta.-L-nucleosides](#)
- 7585626- [Methods for nucleic acid amplification](#)
- 7608632- [Sulfonamide inhibitors of aspartyl protease](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

